Hyung Seok Kim
he/him/his
Visiting Research ScientistCards
About
Research
Publications
2025
Fibrinogen alpha and beta chains as non-invasive predictors of hepatocellular carcinoma progression
Kim H, Choi J, Jang S, Kang M, Yoon M, Baek G, Park W, Han J, Cho H, Jeong J, Cheong J, Kim S, Eun J. Fibrinogen alpha and beta chains as non-invasive predictors of hepatocellular carcinoma progression. Scientific Reports 2025, 15: 42459. PMID: 41309856, PMCID: PMC12660675, DOI: 10.1038/s41598-025-26639-0.Peer-Reviewed Original ResearchConceptsNon-invasive predictorHepatocellular carcinomaDiagnostic accuracyAbundance of myeloid-derived suppressor cellsDisease-free survival ratesMyeloid-derived suppressor cellsStages of hepatocellular carcinomaHepatocellular carcinoma patientsNon-invasive markerGlobal health burdenHepatocellular carcinoma pathogenesisNon-invasive biomarkersSuppressor cellsOverall survivalTumor microenvironmentSerum levelsEffective diagnostic toolDiagnostic efficacyHepatocellular carcinoma progressionA-fetoproteinEarly diagnosisSurvival rateCarcinoma progressionFibrinogen expressionPatient outcomesA Novel Liver-Specific Pseudogene Biomarker, BMS1P8, for Diagnosis and Prognosis in Hepatocellular Carcinoma
Kim H, Choi J, Baek G, Yoon M, Jang S, Han J, Kim S, Cheong J, Jeong J, Eun J. A Novel Liver-Specific Pseudogene Biomarker, BMS1P8, for Diagnosis and Prognosis in Hepatocellular Carcinoma. Frontiers In Bioscience-Landmark 2025, 30: 41684. PMID: 40765359, DOI: 10.31083/fbl41684.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaDiagnostic utilityAssociated with poor survivalEndogenous RNAPatient outcomesStage of liver diseaseReceiver operating characteristic analysisArea under the curveKaplan-Meier statisticsReceiver operating characteristic curveCancer-related mortalityEarly detectionOperating characteristic analysisPersonalized treatment strategiesPublic RNA-seq datasetsClinical HCC samplesLack of effective biomarkersOperating characteristics curveReverse transcription polymerase chain reactionRNA-seq datasetsTranscription polymerase chain reactionNon-tumor tissuesRegulation of biological processesPrognostic valueCeRNACTC-537E7.3 as a Liver-Specific Biomarker for Hepatocellular Carcinoma: Diagnostic and Prognostic Implications
Kim H, Jang H, Baek G, Yoon M, Shim J, Han J, Kim S, Cheong J, Eun J. CTC-537E7.3 as a Liver-Specific Biomarker for Hepatocellular Carcinoma: Diagnostic and Prognostic Implications. Current Issues In Molecular Biology 2025, 47: 563. PMID: 40729031, PMCID: PMC12293479, DOI: 10.3390/cimb47070563.Peer-Reviewed Original ResearchHepatocellular carcinomaEndogenous RNAMechanistic investigationsHCC surveillance strategiesLiver-specific biomarkersDisease-free survivalNon-tumor tissuesSerum a-fetoproteinConcurrent high expressionHigh-risk populationPrognostic implicationsPrognostic potentialDiagnostic performanceA-fetoproteinGEO cohortClinical valueCeRNASurvival analysisEarly-stageSurveillance strategiesPaired tissuesTumorSuperior outcomesLiver-specificHigher expressionA Novel Squaramide Derivative, HR-19011, Induces the Integrated Stress Response via the HRI-eIF2α-ATF4 Pathway, Effectively Inhibiting Hematologic Malignancies.
Kim M, Kwak J, Kim H, Han J, Kang J, Jo J, Kim J, Kim D, Lee H, Yun H, Jeong J. A Novel Squaramide Derivative, HR-19011, Induces the Integrated Stress Response via the HRI-eIF2α-ATF4 Pathway, Effectively Inhibiting Hematologic Malignancies. Molecular Cancer Therapeutics 2025, 24: 1546-1560. PMID: 40293252, DOI: 10.1158/1535-7163.mct-24-0998.Peer-Reviewed Original ResearchConceptsHeme-regulated inhibitorIntegrated stress responseTranscription factor 4Activation of heme-regulated inhibitorStress responseG1/S cell cycle arrestCell cycle regulationIntegrated stress response pathwayCell cycle arrestRNA sequencing analysisFactor 4Sequence analysisDownregulation of componentsISR signalingS6KMTORC1 pathwayGene expressionCell growthPhosphorylated S6KHematologic malignanciesK562 xenograft modelK562 cellsAnticancer effectsTranscriptionPathwayCorrespondence: Response to Editorial on “GULP1, a Multifaceted Biomarker and Therapeutic Target in HCC”
Kim S, Kim H, Cheong J, Eun J. Correspondence: Response to Editorial on “GULP1, a Multifaceted Biomarker and Therapeutic Target in HCC”. Clinical And Molecular Hepatology 2025, 32: e72-e74. PMID: 40181674, PMCID: PMC12835751, DOI: 10.3350/cmh.2025.0350.Peer-Reviewed Original ResearchCorrespondence: Response to the Letter Regarding
Kim H, Kim S, Cheong J, Eun J. Correspondence: Response to the Letter Regarding. Clinical And Molecular Hepatology 2025, 32: e103-e105. PMID: 40107309, PMCID: PMC12835742, DOI: 10.3350/cmh.2025.0287.Peer-Reviewed Original ResearchGULP1 as a Novel Diagnostic and Predictive Biomarker in Hepatocellular Carcinoma
Kim H, Yoon J, Choi J, Yoon M, Baek G, Kang M, Jang H, Park W, Go Y, Ng J, Nam S, Jeong J, Han J, Cho H, Bin Lim S, Kim S, Cheong J, Eun J. GULP1 as a Novel Diagnostic and Predictive Biomarker in Hepatocellular Carcinoma. Clinical And Molecular Hepatology 2025, 31: 914-934. PMID: 39914372, PMCID: PMC12260647, DOI: 10.3350/cmh.2024.1038.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingADP-Ribosylation Factorsalpha-FetoproteinsAnimalsbeta CateninBiomarkers, TumorCarcinoma, HepatocellularCell Line, TumorCell ProliferationEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansLiver NeoplasmsMaleMiceMiddle AgedNeoplasm Recurrence, LocalPrognosisConceptsADP-ribosylation factor 6Epithelial-mesenchymal transitionARF6 activationHepatocellular carcinoma recurrenceCell growthGene Expression Omnibus databaseHepatocellular carcinomaADP-ribosylationGenomic datasetsRisk score modelCancer Genome AtlasExpression modulationFunctional assays in vitroAdaptor 1Signaling pathwayAssay in vitroFactor 6A-fetoprotein levelPredictive gene signaturesHepatocellular carcinoma progressionSelection operator Cox regressionGenome AtlasRisk-scoring modelGenesGene signatureGlycoRNA: A new player in cellular communication
KIM H. GlycoRNA: A new player in cellular communication. Oncology Research Featuring Preclinical And Clinical Cancer Therapeutics 2025, 33: 995-1000. PMID: 40296915, PMCID: PMC12034019, DOI: 10.32604/or.2025.060616.Peer-Reviewed Original Research
2024
The diverse landscape of RNA modifications in cancer development and progression
Kim H, Eun J, Jang S, Kim J, Jeong J. The diverse landscape of RNA modifications in cancer development and progression. Genes & Genomics 2024, 47: 135-155. PMID: 39643826, DOI: 10.1007/s13258-024-01601-y.Peer-Reviewed Original ResearchConceptsRNA-Modifying EnzymesRNA modificationsFunctions of RNA modificationsAberrant RNA modificationsTumor suppressor geneGene expression profilesPreclinical modelsRNA modification patternsRNA speciesNucleotide sequenceRNA functionRNA stabilityChemical marksClinical translationSuppressor geneResponse to immunotherapyModification patternsPatient outcomesGene expressionTumor suppressorDiverse landscapeExpression profilesRNACancer biologyEnzyme
2023
A New Understanding of Long Non-Coding RNA in Hepatocellular Carcinoma—From m6A Modification to Blood Biomarkers
Eun J, Cheong J, Jeong J, Kim H. A New Understanding of Long Non-Coding RNA in Hepatocellular Carcinoma—From m6A Modification to Blood Biomarkers. Cells 2023, 12: 2272. PMID: 37759495, PMCID: PMC10528438, DOI: 10.3390/cells12182272.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Get In Touch
Contacts
Mailing Address
Yale Cancer Center
300 George Street , Rm786
New Haven, CT 06511
United States